Understanding of chemoprophylaxis and concordance in inflammatory bowel disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

249

HTML

1957

Figures (1-1)

201

Tables (1-2)

192

Sum=2599

Feb 7, 2010 (publication date) through Aug 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 7, 2010; 16(5): 578-582
Published online Feb 7, 2010. doi: 10.3748/wjg.v16.i5.578

Table 1 The percentage of patients who agreed with three proposed methods of improving concordance with chemoprophylaxis

Proposed method to improve concordance	Agree (%)	Disagree (%)
Given evidence 5-ASA/UDCA reduces CRC risk	94	6
Once a day preparation	92	8
Clear explanation from Health Professional	87	13

5-ASA: 5-aminosalicylic acid; UDCA: Ursodeoxycholic acid; CRC: Colorectal carcinoma.

Citation: Low A, Love M, Walt R, Kane K, Eksteen B, Goh J. Understanding of chemoprophylaxis and concordance in inflammatory bowel disease. World J Gastroenterol 2010; 16(5): 578-582
URL: https://www.wjgnet.com/1007-9327/full/v16/i5/578.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i5.578